Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Resources Estimates Completed Onshore Morocco

12 Nov 2013 07:00

RNS Number : 7516S
Fastnet Oil & Gas PLC
12 November 2013
 



12 November 2013

Fastnet Oil & Gas Plc

 

("Fastnet" or the "Company")

 

FASTNET ANNOUNCES INDEPENDENT RESOURCES ESTIMATES FOR TENDRARA-LAKBIR, ONSHORE MOROCCO

 

Fastnet (AIM: FAST; ESM: FOI) the listed E&P company focussed on exploration activities in Morocco and in the Celtic Sea, is pleased to announce that an independent assessment of eight Exploration Permits comprising the Tendrara Lakbir Petroleum Agreement (the "Tendrara-Lakbir Licence") onshore Morocco has been completed by SLR Consulting ("SLR"). As announced on 29 May 2013, Fastnet entered into an exclusive option agreement with Oil and Gas Investment Funds ("OGIF") to farm into the Tendrara-Lakbir Licence through its wholly owned subsidiary Pathfinder Hydrocarbon Ventures Limited. A map of the area on is available on the Company's website: http://www.fastnetoilandgas.com/operations/morocco/aspx

 

Highlights:

· New study by specialist Houston-based NuTech petrophysical team quantifies reservoir properties for the Triassic TAGI Sand consistent with good potential gas flow rates from a gross gas-bearing interval in TE-5 of 82.2 meters.

 

· New reservoir engineering study by John Tingas PhD, MSc, Independent Petroleum Engineer, supports development cases, subject to a successful validation of flow rates in an appraisal well on the TE-5 discovery and a step-out appraisal well to the northeast of the TE-5.

 

· New well design study by Dennis Krahn, Chartered Petroleum Engineer, Summit Upstream, supports the enhanced well potential by designing and drilling a conventional appraisal well using modern technologies to minimise and, preferably, eliminate the formation damage seen in previous drilling/testing operations which negatively impacted the well's gas flow rate potential.

 

· New Independent Resources Estimates by SLR, based on these desk top studies and a review of historical published estimates, that were not previously validated by an independent Competent Persons Report, give resource estimates, based on a 65% recovery factor, as follows:

 

TE-5 - LAKBIR STRUCTURE - Gross and Net Contingent Resources

LOW

BEST

HIGH ESTIMATE

Recoverable BCF (100%)

30.1

310.5

891.9

Recoverable BCF (37.5% Net)

11.3

116.4

334.5

Chance of Success (%)

29

22

14

NPV per BCF (US$mm)

N/A

2.29

N/A

Risked Value (ENPV US$mm)

N/A

58.3

N/A

Associated condensate ENPV US$mm

N/A

2.46

N/A

 

 · "Running Room" has also been identified in five additional gas prospects.

 

The SLR report provides an independent assessment and verification of previously published historical resource estimates for the area covered by the Tendrara-Lakbir Licence prior to Fastnet exercising an option to drill an appraisal in 2014 and executing a rig contract. In addition, ahead of drilling the Company also wished to explore the potential options to monetise the discovered gas in the TE-5 - Lakbir Structure by:

· determining the theoretical gas flow rates from the proven gas reservoirs;

· optimising the well design to assist with achieving the maximum potential theoretical flow rates by limiting formation damage whilst drilling, completing and testing;

· seismic re-mapping to assess potential compartmentalisation risks within the larger TE-5 - Lakbir Structure; and

· establishing an outline development plan based on different production profiles to assess the range of field deliverabilities and their impact on any infrastructure and gas demand constraints.

 

The Company recognises that a successful early appraisal of the TE-5 - Lakbir Structure by Fastnet and its partners ONHYM and OGIF has important implications for the strategic planning of Morocco's future gas requirements and the location of new gas-fired power plants. It will enable the validation of the potential Contingent Resources and the potential production profile for any field development scenarios. For this reason early confirmation of the potential scope of the TE-5 - Lakbir Structure to provide indigenous gas to the developing Gas-to-Power options is critical.

 

Fastnet has completed a series of desk-top studies, detailed below, to address these issues and to provide new data for the Independent Resources Report by SLR, on the basis of which the historical published estimates of resources can be assessed and validated.

 

A study by a specialist Houston-based NuTech petrophysical team has quantified reservoir properties for the Triassic TAGI Sand that are consistent with a good potential gas flow rate from a gross gas-bearing interval in TE-5 of 82.2 meters. Significantly an independent petrophysical study has also shown that there is no gas-water contact in the TE-5 well.

 

New seismic depth mapping has shown that the formerly designated TE-5, Lakbir and TE-NE Structures are potentially a single structure with a common gas-water contact in the P50 and P10 Contingent Resources Estimates. This will require verification by a long step-out appraisal well.

 

Critically this work identifies formation damage as a significant issue in previous drilling and testing on the structure which limited absolute gas flow potential from the TE-5 well. In addition, the study identifies that the nature of the permeability characteristics of the TAGI reservoir interval does not facilitate exploitation by horizontal drilling. Furthermore a significant conclusion of the study is that surface compression in a development scenario will reduce well-head pressures and potentially accelerate recovery of gas.

 

Preliminary scoping cost estimates for the above Low, Best and High case development scenarios are provided that allow for scoping economics to be performed for each case.

 

An appraisal well to the TE-5 gas discovery will be required first to validate the potential well deliverability in order to re-calibrate the above potential field production profiles.

 

A new well design study by Dennis Krahn, Chartered Petroleum Engineer, Summit Upstream, supports the enhanced well potential by designing and drilling a conventional appraisal well using modern technologies to minimise and, preferably, eliminate the formation damage seen in previous drilling operations which impacted previous gas flow rate potential. Scoping well costs have been determined based on the design and equipment criteria necessary for optimising drilling operations to ensure good deliverability from the TAGI reservoirs.

 

"Running Room" has also been identified in five additional gas prospects. The full Independent Resources Report by SLR on the Tendrara-Lakbir Licence is available, upon request, on the Company's website at the following address http://www.fastnetoilandgas.com/investor-relations/reports/technical-reports/2013.aspx

 

Commenting, Paul Griffiths, Managing Director of Fastnet, said:

 

"We are pleased that our decision to undertake a series of comprehensive desk-top studies by key specialists with experience and proven track records has been justified by the independent verification of the potential Contingent Resources for the TE-5 - Lakbir Structure. This has provided us with invaluable insight to understand and address the important historical issues related to drilling and completion operations, reservoir quality, reservoir engineering, well performance and the potential for structural compartmentalisation that may have held back the exploitation of the TAGI gas reservoir in the past. An important step in validating the resources potential will be an appraisal well in 2014. It is designed to optimise the flow potential from the TAGI by minimising formation damage as well as collecting high quality flow rate and pressure data with which to validate and re-calibrate the current reservoir engineering studies. We are excited about the drilling of this project as we continue to deliver on our "early mover" strategy. We have again successfully identified and quickly secured dormant high-impact opportunities with latent potential to deliver at the higher end of conventional expectations. Our seasoned technical expertise allowed us to de-risk the asset by addressing key historical issues paving the way to a fast-moving drilling programme based on a sound assessment of geological and well operations risks."

 

For further information please contact:

 

Fastnet Oil & Gas plc

Cathal Friel, Chairman

Paul Griffiths, Managing Director

+353 (1) 644 0007

Shore Capital

Nomad

Bidhi Bhoma, Edward Mansfield

 

Corporate Broking

Jerry Keen

+44 (0) 20 7408 4090

 

Mirabaud Securities LLP

(Joint Broker)

Peter Krens, Edward Haig-Thomas

 

 

+44 (20) 7321 2508

 

Davy

(ESM Adviser & Joint Broker)

John Frain, Anthony Farrell

+353 (1) 679 6363

FTI Consulting

Edward Westropp, Natalia Erikssen

+44 (0) 207 831 3113

 

Notes to editors

 

Fastnet Oil & Gas plc is an independent oil and gas exploration company that focuses on identifying early stage exploration and appraisal opportunities in Offshore Ireland and Morocco. It is quoted on the AIM market of the London Stock Exchange and the Enterprise Securities Market (ESM) of the Irish Stock Exchange. Fastnet's aim is to assemble a portfolio of high impact conventional oil and gas assets that will deliver sustainable growth and value for the Company. Its immediate focus is on implementing its Offshore Ireland and Moroccan strategies where it has been awarded four offshore licensing options in the Celtic Sea (Molly Malone Basin, Shanagarry, 49/13 and Mizzen Basin) and acquired a material interest in the Foum Assaka permit Offshore Morocco alongside an exclusive option agreement over the Tendrara-Lakbir Licence which covers 8 exploration blocks. In addition, Fastnet will continue to pursue new conventional oil and gas opportunities in Africa where the Directors and Advisory Board also have extensive knowledge, contacts and experience of creating value.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DRLNKDDDCBDDQDD
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.